MindWalk Holdings (HYFT) Liabilities and Shareholders Equity (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Liabilities and Shareholders Equity of $15.6 million for Q2 2026, down 50.07% year-over-year from $31.2 million in Q2 2025, and down 5.86% quarter-over-quarter from $16.6 million in Q1 2026.
MindWalk Holdings (HYFT) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $15.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Liabilities and Shareholders Equity fell 50.07% year-over-year to $15.6 million; the TTM figure through Apr 2026 stood at $80.6 million (down 46.43% YoY), while the FY2026 annual figure was $15.6 million, down 51.12% from the prior year.
- Liabilities and Shareholders Equity eased to $15.6 million in Q2 2026 per HYFT's latest filing, from $16.6 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $73.9 million in Q2 2022 and bottomed at $15.6 million in Q2 2026.
- Historically, Liabilities and Shareholders Equity has averaged $44.9 million across 5 years, with a median of $44.4 million in 2022.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 39.02% — and 2025, when it plunged 57.15%.
- MindWalk Holdings' Liabilities and Shareholders Equity stood at $62.3 million in 2022, then declined by 10.5% to $55.8 million in 2023, then decreased by 21.25% to $43.9 million in 2024, then slumped by 57.15% to $18.8 million in 2025, then declined by 17.13% to $15.6 million in 2026.
- Business Quant data shows HYFT's Liabilities and Shareholders Equity at $15.6 million in Q2 2026, $16.6 million in Q1 2026, and $18.8 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 15.59 Mn |
| Jan 31, 2026 | 16.56 Mn |
| Oct 31, 2025 | 18.82 Mn |
| Jul 31, 2025 | 29.66 Mn |
| Apr 30, 2025 | 31.23 Mn |
| Jan 31, 2025 | 32.08 Mn |
| Oct 31, 2024 | 43.91 Mn |
| Jul 31, 2024 | 43.31 Mn |
| Apr 30, 2024 | 44.24 Mn |
| Jan 31, 2024 | 58.21 Mn |
| Oct 31, 2023 | 55.76 Mn |
| Jul 31, 2023 | 57.38 Mn |
| Apr 30, 2023 | 57.51 Mn |
| Jan 31, 2023 | 61.12 Mn |
| Oct 31, 2022 | 62.31 Mn |
| Jul 31, 2022 | 62.16 Mn |
| Apr 30, 2022 | 73.94 Mn |
| Jan 31, 2022 | 44.60 Mn |
| Oct 31, 2021 | 47.99 Mn |
| Jul 31, 2021 | 52.45 Mn |